Iteos Therapeutics Inc
ITOS10.095USD
+0.005+0.05%
收盘 08/04, 16:00（美东）报价延迟15分钟
386.35M总市值
亏损市盈率 TTM
关于 Iteos Therapeutics Inc 公司
iTeos Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于为癌症患者发现和开发新一代免疫肿瘤疗法。其产品线包括三个临床阶段项目，针对新颖、经过验证的免疫肿瘤途径。其主要抗体候选产品 belrestotug（也称为 EOS-448/GSK4428859A）是 TIGIT 的拮抗剂，TIGIT 是一种具有多种作用机制的免疫检查点。其高级项目是 inupadenant，也称为 EOS-850，这是一种下一代腺苷 2A 受体 (A2AR) 拮抗剂，专门用于克服肿瘤微环境中发现的特定腺苷介导的免疫抑制。其启动临床试验的项目是 EOS-984，这是一种潜在的同类首创小分子，专注于腺苷途径中的一种新机制，通过靶向平衡核苷转运蛋白 1（ENT1），即参与 T 细胞代谢的淋巴细胞上腺苷的主要转运蛋白。
公司简介
公司代码ITOS
公司名称Iteos Therapeutics Inc
上市日期Jul 24, 2020
CEODr. Michel Marcel Detheux, Ph.D.
员工数量173
证券类型Ordinary Share
年结日Jul 24
公司地址321 Arsenal Street
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02472
电话18572044583
网址https://www.iteostherapeutics.com/
公司代码ITOS
上市日期Jul 24, 2020
CEODr. Michel Marcel Detheux, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Matthew Gall
Mr. Matthew Gall
Chief Financial Officer
Chief Financial Officer
89.43K
+36.68%
Dr. Yvonne Mcgrath, Ph.D.
Dr. Yvonne Mcgrath, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.30K
+49.35%
Mr. David L. Hallal
Mr. David L. Hallal
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
200.00
--
Dr. David Feltquate, M.D., Ph.D.
Dr. David Feltquate, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
--
Dr. Tony W. Ho, M.D.
Dr. Tony W. Ho, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Call
Mr. Matthew (Matt) Call
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Jill Desimone
Ms. Jill Desimone
Independent Director
Independent Director
--
--
Mr. David K. Lee
Mr. David K. Lee
Independent Director
Independent Director
--
--
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Matthew Gall
Mr. Matthew Gall
Chief Financial Officer
Chief Financial Officer
89.43K
+36.68%
Dr. Yvonne Mcgrath, Ph.D.
Dr. Yvonne Mcgrath, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.30K
+49.35%
Mr. David L. Hallal
Mr. David L. Hallal
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
200.00
--
Dr. David Feltquate, M.D., Ph.D.
Dr. David Feltquate, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
--
Dr. Tony W. Ho, M.D.
Dr. Tony W. Ho, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月4日 周五
更新时间: 7月4日 周五
持股股东
股东类型
持股股东
持股股东
占比
EcoR1 Capital, LLC
24.20%
Tang Capital Management, LLC
8.66%
BVF Partners L.P.
6.96%
BlackRock Institutional Trust Company, N.A.
6.61%
RA Capital Management, LP
4.83%
Other
48.73%
持股股东
持股股东
占比
EcoR1 Capital, LLC
24.20%
Tang Capital Management, LLC
8.66%
BVF Partners L.P.
6.96%
BlackRock Institutional Trust Company, N.A.
6.61%
RA Capital Management, LP
4.83%
Other
48.73%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
44.00%
Hedge Fund
32.73%
Investment Advisor
18.71%
Venture Capital
4.83%
Research Firm
4.03%
Individual Investor
1.18%
Bank and Trust
0.24%
Pension Fund
0.04%
Family Office
0.03%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
356
46.25M
106.55%
-2.06M
2025Q1
370
38.09M
99.61%
-6.00M
2024Q4
371
35.32M
96.67%
-8.51M
2024Q3
369
38.37M
105.07%
-5.97M
2024Q2
373
37.75M
104.49%
-5.18M
2024Q1
379
35.71M
99.63%
-7.84M
2023Q4
383
36.12M
100.93%
-6.72M
2023Q3
372
36.95M
103.27%
-4.10M
2023Q2
371
36.77M
102.82%
-4.92M
2023Q1
370
37.66M
105.32%
-4.62M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
EcoR1 Capital, LLC
10.69M
27.93%
+10.69M
--
May 15, 2025
Tang Capital Management, LLC
3.83M
10%
--
--
Jun 11, 2025
BVF Partners L.P.
3.08M
8.03%
+750.00K
+32.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.92M
7.63%
+313.58K
+12.03%
Mar 31, 2025
RA Capital Management, LP
2.13M
5.58%
-1.51M
-41.50%
May 19, 2025
Ridgeback Capital Management, L.P.
1.44M
3.77%
+1.44M
--
May 28, 2025
683 Capital Management LLC
1.75M
4.57%
+831.88K
+90.61%
Mar 31, 2025
The Vanguard Group, Inc.
1.73M
4.51%
+92.43K
+5.66%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.22M
3.18%
+383.07K
+45.83%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.18M
3.09%
-28.83K
-2.38%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
ALPS Medical Breakthroughs ETF
0.26%
JPMorgan Fundamental Data Science Small Core ETF
0.22%
iShares Micro-Cap ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Avantis US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.9%
ALPS Medical Breakthroughs ETF
占比0.26%
JPMorgan Fundamental Data Science Small Core ETF
占比0.22%
iShares Micro-Cap ETF
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Avantis US Small Cap Equity ETF
占比0.04%
iShares Biotechnology ETF
占比0.04%
Invesco RAFI US 1500 Small-Mid ETF
占比0.03%
Fidelity Enhanced Small Cap ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
